Coya Therapeutics (NASDAQ:COYA) Shares Up 0.2% – Here’s Why

Posted by Francis Steltz on Jul 25th, 2026

Coya Therapeutics, Inc. (NASDAQ:COYA – Get Free Report) was up 0.2% during mid-day trading on Thursday . The company traded as high as $4.43 and last traded at $4.38. Approximately 240,962 shares traded hands during mid-day trading, a decline of 10% from the average daily volume of 267,532 shares. The stock had previously closed at $4.37.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on COYA. Roth Capital began coverage on Coya Therapeutics in a research report on Friday, June 5th. They set a “buy” rating and a $12.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Friday, July 17th. Wall Street Zen lowered Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. D. Boral Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a research note on Friday, April 10th. Finally, Chardan Capital restated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Friday, June 12th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.33.

View Our Latest Stock Report on Coya Therapeutics

Coya Therapeutics Price Performance

The firm’s fifty day moving average is $4.95 and its two-hundred day moving average is $4.70. The firm has a market cap of $99.70 million, a price-to-earnings ratio of -3.70 and a beta of 0.51.

Coya Therapeutics (NASDAQ:COYA – Get Free Report) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. The company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.15 million. Coya Therapeutics had a negative return on equity of 55.86% and a negative net margin of 266.10%. On average, equities analysts forecast that Coya Therapeutics, Inc. will post -1.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Alyeska Investment Group L.P. acquired a new stake in shares of Coya Therapeutics during the 4th quarter valued at about $4,640,000. AWM Investment Company Inc. bought a new position in Coya Therapeutics during the fourth quarter worth about $4,205,000. Private Management Group Inc. acquired a new stake in Coya Therapeutics during the fourth quarter valued at approximately $1,626,000. Marshall Wace LLP boosted its holdings in Coya Therapeutics by 438.8% during the fourth quarter. Marshall Wace LLP now owns 225,358 shares of the company’s stock valued at $1,307,000 after purchasing an additional 183,533 shares in the last quarter. Finally, Dauntless Investment Group LLC grew its stake in shares of Coya Therapeutics by 199.5% in the 3rd quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after purchasing an additional 101,932 shares during the period. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

(Get Free Report)

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.